Androgen receptor (AR), is a transcription factor and a member of a hormone receptor superfamily. AR plays a vital role in the progression of prostate cancer and is a crucial target for therapeutic interventions. While the majority of advanced-stage prostate cancer patients will initially respond to the androgen-deprivation, the disease often progresses to castrate-resistant prostate cancer (CRPC). Interestingly, CRPC tumors continue to depend on hyperactive AR signaling and will respond to potent second-line anti-androgen therapies, including bicalutamide (CASODEX Ò ) and enzalutamide (XTANDI Ò ). However, the progression-free survival rate for the CRPC patients on antiandrogen therapies is only 8 to 19 months. Hence, there is a need to understand the mechanisms underlying CRPC progression and eventual treatment resistance. Here, we have leveraged next-generation sequencing and newly developed analytical methodologies to evaluate the role of AR-signaling in regulating the transcriptome of prostate cancer cells. The genomic and pharmacologic stimulation-and inhibition-of AR activity demonstrates that AR regulates alternative splicing within cancer-relevant genes.
Introduction
Androgen receptor (AR) is a member of the superfamily of hormonal nuclear receptors 1 . In the absence of its ligand, AR is secured in the cytoplasm by heat-shock proteins 2 . Once exposed to the male hormone androgen, AR, becomes activated, and translocates to the nucleus, where it binds to the androgen response elements (ARE) and initiate the transcriptional program [3] [4] [5] [6] [7] . Interestingly, activated AR molecules both enhance and suppress the expression of genes involved in prostate cancer progression [8] [9] [10] [11] [12] [13] . This hormone-driven AR signaling is essential for development, differentiation, and normal functioning of the prostatic gland 14 . AR signaling, however, is hijacked in prostate tumors, driving disease progression. Therefore, the blockage of AR signaling through androgen deprivation continues to be the mainstay treatment of advanced-stage prostate cancer. While almost all patients with metastatic disease will initially respond to androgen ablation therapies, the majority of patients will progress to a castrate-resistant stage [15] [16] [17] [18] .
Interestingly, studies employing xenograft prostate tumor models have shown that CRPC tumors that emerge after androgen-ablation therapy, continue to express AR and AR regulated genes 19 . Recent studies have argued that kinase-mediated hypersensitivity of AR [20] [21] [22] [23] [24] and efficient uptake of androgens may play a critical role in fueling CRPC tumors 25 . Thus, the treatment option for patients with non-metastatic or metastatic CRPC typically includes high-affinity anti-androgens like bicalutamide (CASODEX Ò ) and enzalutamide (XTANDI Ò ) [26] [27] [28] . Although, in recent trials, enzalutamide has shown improved efficacy in comparison to bicalutamide the median time to PSA progression still suggests a limited benefit that lasts no more than 8 to 19 months 29 . In addition, in a few cases, an increase in metastasis of the disease was reported to be associated with the AR antagonist's treatment regimen. Therefore, the search for the mechanism underlying CRPC, CRPC progression, and eventual treatment resistance would benefit patients who have exhausted all currently available treatment options. Towards this effort, the comprehensive understanding of AR functions continues to remain the center of focus.
The recent advent of high-throughput RNA sequencing and splicing microarrays has unveiled new layers of regulation of gene expression and highlighted the extreme complexity and versatility of the transcriptome. The majority of human genes encode multiple transcripts through the use of alternative promoters, alternative splicing (ASE), and alternative polyadenylation 30 . ASE is a mechanism that significantly expands the functional potential of the genome either by altering the usage of protein-coding transcripts, the ratio of coding to non-coding transcripts, or by allowing expression of isoforms with antagonistic functions from a single gene 31 . Multiple studies have found that ASE play a critical role in cancer 32 . A recent comprehensive analysis of alternative splicing across 32 cancer types from 8,705 patients revealed that tumors have up to 30% more alternative splicing events than normal tissues 33 . The steroid nuclear hormone receptors, including estrogen and progesterone receptors, are known to recruit regulators of ASE and modulate the transcriptome 34, 35 . However, whether modulation of ARsignaling may alter transcriptome of prostate cancer cells remains largely unexplored.
Herein, we hypothesized that modulation of AR-signaling either during prostate cancer progression or in response to treatment with AR antagonists might dysregulate the transcriptome of prostate cancer cells by modulating ASE. We employed a multitude of genomic approaches including Affymetrix splicing array, whole transcriptome RNA-seq analysis, and RT-PCR to show that AR-signaling regulates the transcriptome of prostate cancer cells by modulating ASE of a wide array of genes involved in regulating protein function. Furthermore, leveraging publicly available transcriptome data of primary-site samples from patients with prostate cancer at various stages of progression, we found a subset of AR-driven splicing events that are associated with progression of prostate cancer. Mechanistically, we found that Epithelial Splicing Regulator Proteins (ESRP1 & ESRP2) are the splicing factor through which AR may regulate splicing of pre-mRNA in prostate cancer cells. Interestingly, the inhibition of ESRPs suppressed AR-antagonist mediated increase in the invasion of prostate cancer cells. Collectively, we provide the evidence for a novel and critical mechanism of prostate cancer progression that is regulated by AR and that the treatment with AR-antagonist may inadvertently promote invasion by dysregulating splicing of critical genes.
Pharmacological Manipulation of Androgen Receptor Signaling Induces

Alternative Splicing in Prostate Cancer Cells
To study the effect of pharmacological manipulation of AR signaling in prostate cancer cells, we performed expression profiling of LNCaP cells that were cultured for 72 hours in charcoal-stripped fetal bovine serum and stimulated with 10nM AR agonist, dihydrotestosterone (DHT), or 10uM of the AR antagonist casodex for 24 hours. The array consisted of > 6 million probes, of which 70% covered exons for coding transcripts while the remaining 30% covered exon-exon splice junctions and non-coding transcripts;
hence, allowing us to monitor transcriptional changes at the level of the exon. Besides, the well-characterized gene expression changes ( Supplementary Table 1 ), we found that pharmacological manipulation of AR signaling induced global changes in ASE, which was evident by differential expression of exon-exon splice junction probes in comparison to constitutive exons (Supplementary Table 2 ). Figure 1A shows the expression of top-50 differentially expressed probes spanning exon-exon junction of a gene across different conditions. We next sought to characterize the potential ASE events using the transcription analysis console, which integrates the evidences from array probes spanning exon-exon splice junction and constitutive exons to classify the events as either cassette exon (CE), alternative 3 prime start site (A3SS), alternative 5 prime start site (A5SS), intron retention (IR), complex event, alternative last exon (ALE), mutually exclusive exon (MEE), or alternative first exon (AFE) ( Figure 1B ). Because changes in gene expression may confound ASE call, we filtered out any splicing events that occurred within gene that were differentially expressed in treatment group in comparison to control.
In summary, treatment of LNCaP cells with DHT or casodex resulted in 671 and 2127 significant ASE events in comparison to DMSO treatment respectively. Furthermore, in comparison to stimulation, inhibition of AR in LNCaP cells led to greater than 2827 ASE events. We found that treatment of LNCaP cells with antagonist or agonist did not drastically alter the distribution of CE (63% vs 84%), A3SS (12% vs 6%), A5SS (15.0% vs 8.0%), ALE (0.2% vs 0%), MEE (0% vs 0.1%), and AFE (0.1% vs 0%). However, treatment with casodex did show a ten-fold increase (11.0% vs 1.0%) in the percentage of IR events in comparison to agonist treated LNCaP cells. 
RNAseq-EnzVsDHT
Affy-CasodexVsDHT
Comparison Between Affy and RNA
Figure
We next sought to validate the ASE events predicted by the splicing array using RT-PCR assay. The CE and IR are some of the most common splicing events contributing towards transcriptional heterogeneity in tumor cells and are also well characterized 33, [36] [37] [38] . Therefore, we decided to validate a total of 15 of these events in three separate cell lines including LNCaP, 22RV1 (castrate-resistant prostate adenocarcinoma cells), and PC3 (bone metastatic prostate cancer cells). We performed three independent experiment each with three technical replicates. The ASE events for validation were picked based on the following three criteria 1) Events with FDR cut off of 0.05 and SI of >= |2|; 2) Events with evidence from not only the probes mapping to the alternatively spliced region but also those that mapped to junction surrounding it, and 3)
Genes with a known biological role in cancer. We used two primer pairs, one for monitoring the expression of constitutive exons within all the isoforms of a gene and another for measuring changes in the alternatively spliced region. The primers specific to the constitutive exons revealed that LNCaP cells express 15 genes, 22RV1 express 13, and PC3 cells express 14 of 15 genes tested (Supplementary Table 3 ). The RT-PCR assay validated 47%, 53%, and 28% of HTA-2.0 predicted splicing events in LNCaP, 22RV1, and PC3 cells respectively ( Figure 1C and Supplementary Figure 1 Supplementary Table 4 ).
We next leveraged publicly available and in-house generated whole transcriptomic data to investigate whether treatment with enzalutamide, a more potent AR antagonist than casodex would also induce ASE in LNCaP cells. Briefly, we performed strandspecific 150-bp paired-end RNA-seq for LNCaP cells treated with vehicle or 10nM DHT.
Additionally, we downloaded a dataset for enzalutamide or vehicle treated LNCaP cells from GSE110903. Altogether, we compiled data consisting of two biological replicates per sample with 45-80 million mapped reads per replicate. We used the rMATS computational pipeline with default settings to identify the splicing changes. The analysis revealed that DHT and enzalutamide treatment induced 198 and 167 significant ASE events respectively at a stringent filter of FDR <= 0.05 and delta PSI of >= 10%. The largest difference in ASE (~5663) was observed when we compared the transcriptome of LNCaP treated with enzalutamide with that of DHT ( Figure 1D ). Furthermore, rMATS classification of enzalutamide or DHT induced ASE revealed that the majority of splicing Figure 4A . Moreover, splicing analysis using whole transcriptome and splicing array data are reported to produce discordant results and consistent with that observation we too found a very small overlap (377/4265) between genes identified to undergo ASE upon treatment with casodex or enzalutamide ( Figure 1E ). Overall, evidence from analysis of splice array, RT-PCR and whole transcriptome data supports our novel observation that modulation of AR signaling alters transcriptome of prostate cancer cells by regulating ASE.
Functional Analysis of Genes Regulated at the Level of Alternative Splicing and Transcription in Prostate Cancer Cells
In order to study the significance of ASE in prostate cancer cells that are driven by pharmacological manipulation of AR signaling, we first queried whether treatment with enzalutamide or casodex altered splicing of prostate cancer relevant genes. We curated a list of 100 genes (Supplementary Figure 2A . One of the RT-PCR validated ASE prostate cancer genes is IDH1, a key metabolic gene regulating TET2 mediated epigenetic re-programing in prostate tumor cells 39, 40 . We found that casodex treatment of all three prostate cancer cell lines resulted in a switch from ENST00000345146, a dominant transcript of IDH1 to ENST00000415913 with an alternate 5'UTR ( Supplementary Figure 1) . The translational relevance of this functional switch was accentuated by our expression and survival analyses, which revealed that the expression of the primary isoform (ENST00000345146) is significantly higher (p = 1.84e-43) in the TCGA-Prostate Adenocarcinoma tissue (N = 495) in comparison to the GTEX-normal prostate tissue (N = 100) and is also associated with decreased overall patient survival ( Figure 2B ). 
Casodex vs DHT
We further investigated whether genes modulated by casodex and DHT at the level of transcription and ASE have different physiological roles. We derived biological roles for this exclusive set of AR-axis modulated genes by using gene ontology (GO) overrepresentation analysis. We used all the genes that have an annotation as reference in our analysis as recommended by clusterProfiler. The alternatively spliced genes were enriched in pathways related to modulation of gene expression including nucleic acid, protein transport, mRNA splicing, and proteosomal degradation whereas the differentially expressed genes were enriched in pathway related to EMT including those involved in GTPase activity, cell-cell interaction/junctions, and cytoskeleton organization ( Figure 2C ).
We next leveraged RNAseq data from enzalutamide and DHT treated cells to investigate the potential mechanisms of action through which ASE may alter function of a gene.
Briefly, we mapped the region undergoing ASE to protein domains of the gene using Maser R package. We found that the majority of splicing occurred in the characterized functional domains including the transmembrane domain, coiled region, topo domain, metal binding, zinc finger binding, and activation site for protein (Supplementary Figure   4B ). Furthermore, similar to casodex, enzalutamide treatment of LNCaP cells also dysregulated splicing of genes enriched in pathways involved in the modulation of gene expression including splicing, transport of nucleic acid, proteasomal degradation, and protein localization ( Figure 2D ). Collectively, our results strongly suggest that the changes in androgen-driven ASE are biologically meaningful and distinct from the functional impact of androgen-driven gene expression changes.
Direct Genomic Inhibition of Androgen Receptor in Prostate Cancer Cells Induces
Alternative Splicing.
Our data provides evidence for the AR agonist and antagonist mediated regulation of ASE of pre-mRNA. However, it is possible that the observed ASE is a non-specific effect from the pharmacological treatment of cells and not a direct effect by modulation of AR. To test this possibility, we modulated expression of AR in 22RV1 cells using siRNA and used RT-PCR assays to study altered splicing of genes including AAK1, SYNE4, and MAN1A1 which were predicted to undergo ASE in response to casodex treatment. We found a robust five-fold decrease in the expression of AR in 22RV1 cells transfected with
siRNA in comparison to a scrambled siRNA ( Figure 3A ). Supporting our hypothesis, we found that the five-fold inhibition of AR altered splicing of AAK1 (SI: -2.52), SYNE4 (SI: -1.36), and MAN1A1 (SI: -3.22) in the same direction as that of casodex ( Figure 3B , Supplementary Table 4 ). This data supports our hypothesis that ASE events induced by agonists or antagonists of AR are driven in part by direct modulation of AR.
We next leveraged publicly available (GSE110903) RNAseq data to further study the effects of genomic inhibition of AR on ASE in MDA-PCa-2b cells, a model for advanced prostate cancer bone metastasis cells that express PSA, AR and are androgen sensitive. The rMATS analysis revealed that siRNA knockdown of AR in MDA-PCa-2b cells induced 3841 ASE events after a stringent filtration of FDR <= 0.05 and delta PSI of >= 10%. Also, similar to our observations with enzalutamide treated LNCaP cells, we found that the MEE formed the largest fraction of ASE events induced by the siRNA knockdown in MDA-PCa-2b and were followed by CE and IR events ( Figure 3C ). In addition, we used the upset plot for identifying the overlap between genes that are regulated at the level of splicing by the pharmacological inhibitors of AR in LNCaP cells or genomic inhibition of AR in MDA-PCa-2b. We found an overlap of 984 genes between enzalutamide treated LNCaP and siRNA treated MDA-PCa-2b cells, 424 genes between casodex and enzalutamide treated LNCaP cells, and 207 genes between casodex treated LNCaP and siRNA treated MDA-PCa-2b cells. Interestingly, 323 genes were common between all three treatment groups and were enriched for pathways involved in the regulation of translation ( Figure 3D , Supplementary Figure 4C ). The plot also revealed a non-overlapping set of genes in all treatment groups, possibly indicating a combination of differences in prostate cell line models and assays used for measuring ASE. The ASE genes also included known prostate cancer relevant genes including CTNNB1, AKT1, LEF1, and VDR. The heatmap comparing PSI for prostate cancer genes across MDA-PCa-2b cells treated with scrambled or siRNA against AR ( Figure 3E ). Similar to enzalutamide treated LNCaP cells, the GO pathway analyses revealed that genes undergoing ASE modulated by genomic inhibition of AR are enriched for pathways including mRNA splicing, translation initiation, chromatin remodeling, epigenetic regulation, and proteasomal degradation ( Figure 3F ). In addition, the functional mapping of alternatively spliced exons revealed that genomic inhibition of AR may dysregulate Supplementary Table 1 ). Furthermore, numerous studies have also reported that splicing is enhanced when ESRP1/2 binds to pre-mRNA downstream of the exon, while splicing is enhanced when ESRP1/2 binds upstream of or within the exon. Therefore, to gain additional support for the interplay between ESRP1/2 and AR, we performed spatial analysis of ESRP1/2 binding sites around the exons that are alternatively spliced in response to pharmacological inhibition of AR in the LNCaP cell line. We performed a spatial analysis for all the significant cassette exon events in LNCaP cells treated with enzalutamide in comparison to DHT. Furthermore, ESRP1/2 are involved in EMT and invasion of cancer cells 42, 43 .
However, the role of ESRP1/2 in prostate cancer has not been established. In order to study the significance of the AR-ESRP axis in prostate cancer, we employed an in vitro invasion assay. Consistent with published in vitro and in vivo report 44 Our analysis in prostate cancer cell lines shows that modulation of AR signaling dysregulates splicing of functionally relevant genes. Since dysregulation of AR signaling is the hallmark of prostate cancer progression, we hypothesized that ASE of functionally relevant genes would be associated with the progression of disease. To test our hypothesis, we employed rMATS splicing analysis using GSE80609 45 ESYT2. The direction of PSI for these events varied during disease progression, suggesting a differential role for these genes in disease ( Figure 5B ). Supplementary Figure 5D -K shows the transcript plots displaying the usage of exon for these nine genes between AdvPC and CRPC. The transcriptome of advPC and CRPC is reported to be highly similar and previous study had identified only 15 genes that differentiated their transcriptome. Hence, we further investigated whether ASE events may further distinguish advPC from CRPC. We compared the list of splicing events in paired and unpaired samples of advPC and CRPC (CÇD) and found 13 unique splicing events that differentiated the transcriptome of advPC and CRPC (Supplementary Figure 5A -C).
These splicing events occurred in the pre-mRNA of PTGR1, FRG1HP, RP11, CA5BP1, CREM, TNRC6B, BCS1L, FASTKD1, ESYT2, CLN3, PLA2G2A, MYL6, FBXL12, ZNF202, UBAP2, and MIR940 (Supplementary Figure 5L) . The rMATS analysis of the prostate cancer dataset identified that ASE is associated with tumorigenesis, advanced progression, and CRPC development. Furthermore, in addition to differentially expressed genes, our study identifies splicing events that can further differentiate the transcriptome of advPC and CRPC.
Our analysis shows that pharmacological or genomic inhibition of AR alters splicing of several functionally relevant genes. Therefore, it is possible that a subset of these alternatively spliced genes is associated with progression of prostate cancer. To test this possibility, we compared the list of splicing events common across all stages of prostate cancer (AÇBÇCÇD) and list of splicing events induced by either pharmacological and genomic inhibition of AR in LNCaP and MDA-PCa-2b cells (Supplementary Figure 5A -C). We found only one significant event that alters the inclusion of exon-2 (Chr1:19979580-19979659) in the pre-mRNA of PLA2G2A, a secreted phospholipase.
PLA2G2A is significantly downregulated in patients with metastatic prostate cancer in comparison to the primary tumor. Moreover, the decrease in expression of PLA2G2A is implicated in promoting invasion and metastasis 46 . Interestingly, exon-2 of PLA2G2A contains a repressor region, and its inclusion is associated with a decrease in the expression of the gene 47, 48 . In support of the known role of PLA2G2A, we found an increase in the inclusion of exon-2 in advPC in comparison to CRPC (paired and unpaired samples), BPH in comparison to L.PC (unpaired samples) and in response to the pharmacological or genomic inhibition of AR signaling in LNCaP and MDA-PCa-2b cell lines respectively ( Figure 5C ).
To study the functional significance of the exon-2 splicing, we performed expression and survival analysis with the TCGA-PRAD and GTEX datasets. In particular, we found that percentage of the ENST00000375111.7 isoform, that contains exon 2 was significantly higher in patients with prostate cancer (n = 496, TCGA-PRAD) in comparison to healthy prostate tissue (n = 100, GTEX-prostate). In contrast, the percentage of the ENST00000400520.7 isoform, that does not contain exon 2 was significantly lower in patients with prostate cancer in comparison to healthy prostate ( Figure 5D ). In addition, the survival analysis for primary prostate cancer patients in TCGA dataset revealed that patients with primary tumors with a higher difference between percentage isoform of ENST00000375111.7 than ENST00000400520.7 (> 18.17; n = 122) had significantly (p = 0.021) shorter overall survival (OS) compared to those difference of < 4.08 (n = 123) ( Figure 5E ).
In conclusion, we show that differential usage of exon or introns is associated with progression of prostate cancer. In addition, inhibition of AR may inadvertently switch the delicate balance between different splice isoforms in genes critical for disease progression. Interestingly, our work revealed that inhibiting AR-signaling using Casodex and enzalutamide significantly increases intron retention in comparison to DHT treatment.
Supplementary Figure 5
Intron retention is known to generate abnormal transcripts that are translated into immunogenic peptides, loaded on MHC-1, and presented to the immune system 50 .
Therefore, patients with advanced-stage prostate cancer undergoing treatment with ARinhibitors may have a higher neoepitope load and hence benefit from immune checkpoint inhibitors. Further studies will be necessary to predict and validate the immunogenicity of neoepitopes generated in response to AR-inhibitors, including identification of T cells infiltrating prostate tumors specific to predicted neoepitopes.
AR molecules in the cytoplasm dimerize and translocate to the nucleus in response to androgens and regulate the expression of target genes. Therefore, a majority of published reports have performed enrichment analysis with differentially expressed genes to understand the physiological significance of AR-signaling. In our work, we tested whether the AR-signaling regulated alternative splicing of pre-mRNA, has a different physiological role than that from differentially expressed genes. We found that while inhibiting AR-signaling led to expression changes of genes involved in EMT, it also The regulation of alternative splicing is primarily mediated by RBPs that interact with sequences flanking exon and introns as splicing enhancers or silencers, depending on the regulator and binding context. AR is a transcription factor; therefore, we argued that one mechanism through which it may regulate ASE is by modulating the expression of RBPs. We tested 112 well-characterized RBPs and found that only ESRP1/2 were transcriptionally regulated by pharmacological inhibitors of AR. Furthermore, consistent with the known mechanism for ESRPs driving splicing, we found that the binding sites for
ESRPs were enriched or under-represented in the region within and flanking the ARregulated cassette exon events. These data provide strong evidence for AR-ESRP axis driven cassette exons events in prostate cancer cells. We will need to perform ChIP-Seq to directly validate whether androgens or anti-androgens dysregulate ESRP binding around AR-driven cassette exons. Also, it would be interesting to study whether AR and ESRP bind within the same region and are part of a protein complex regulating splicing.
Because ESRP plays a critical role in EMT and tumor invasion in several tumor types 43 , we hypothesized that the AR-ESRP axis might be critical for promoting metastasis either by promoting EMT or promoting invasion. Moreover, although pharmacological inhibitors of AR-signaling suppress tumor growth, we and others have shown using in vitro and in vivo approaches that it also promotes invasion of tumor cells 44 .
Hence, it is critical to identify new therapeutic targets that may alleviate accidental invasion promoting effects of inhibiting AR-signaling in advanced state prostate cancer.
Our in vitro invasion assay found that silencing ESRP protein abrogates a Casodex mediated increase in the invasion of prostate cancer cell lines. Thus, a small molecule inhibitor for ESRP may serve as an attractive avenue to counter the invasion promoting phenotype of AR inhibitors.
Our work using prostate cancer cell lines showed that AR-signaling dysregulates the splicing of functionally relevant genes. Because AR-signaling is a hallmark of prostate cancer progression, we also investigated whether AR-regulated ASE is associated with the progression of disease. Our analysis showed that significant splicing events are occurring during different stages of prostate cancer progression. Contrary to an earlier study 45 , which had found that dysregulation of the expression of AR was associated with all stages of prostate cancer, we found an additional nine splicing events. Therefore, our work reveals a new potential area of inquiry into the underlying biology of prostate cancer initiation and progression to the castrate-resistant stage.
Furthermore, the transcriptomic analysis had only identified 15 genes that were differentially expressed between advPC and CRPC, thus making these two stages of cancer challenging to differentiate genetically. By focusing on alternative splicing, we have now identified an additional 13 genes that are differentially spliced between advPC and CRPC. Thus, a combined gene expression and splicing panel could potentially have a higher diagnostic value to discriminate patients in an advanced stage from the one with the castrate-resistant disease.
Lastly, we investigated whether the treatment of prostate cancer cells with pharmacological inhibitor enzalutamide may lead to an inadvertent switch in the splicing of a pre-mRNA and promote tumor progression. Our analysis found that dysregulation of AR-signaling in prostate cancer driven by enzalutamide treatment increases the inclusion of exon-2 of the PLA2G2A gene in prostate cancer cells. The translational significance of the inclusion of exon-2 was validated in the TCGA PRAD, where we revealed that the PLA2G2A isoform that includes exon-2 is a prognostic factor for outcomes (O.S), providing strong evidence for developing a therapeutic strategy that can mitigate the inadvertent pro-tumorigenic effects of inhibiting AR-signaling.
In conclusion, this study highlights the so-far undescribed role of AR in modulating gene expression via alternative splicing in prostate cancer. This discovery also opens a new therapeutic path and supports the rationale for using ESRP inhibitors in combination with AR-antagonists for the treatment of advanced-stage prostate cancer to counteract the AR-antagonist driven invasive phenotype. 
Materials & Methods
Reagents
Western Blotting
Cells were dissolved in RIPA buffer (sigma). Protein concentration was measured by BCA protein assay reagent kit (Pierce, Rockford, IL, USA), as described previously. Proteins 
Reverse Transcription PCR Validation for Splicing Events
A total validation of 15 splicing events was performed on three prostate cancer cell lines High-quality RNA samples were extracted and illumine library were constructed as described earlier. Libraries were pooled and diluted for sequencing with a 1% PhiX spikein according to Illumina protocol. The pool of library was loaded onto the HiSeq was performed using a 300-cycle high output v2 kit. Reads were obtained from sequencer or were downloaded from GEO. Adapter sequences and invalid reads containing poly-N and low-quality were removed using the FastX tool kit (v 0.0.14). The quality of reads was then confirmed using fastqc tool kit (v 0.11.5). All downstream analysis used the cleaned reads. The clean reads were mapped to the ENSEMBL built GRC38 using the STAR aligner (v2.5.3a) using ENCODE option as described in the STAR manual. Differentially expression of genes was obtained using the DESeq2 method as described earlier.
Subsequently, we used rMATS (version3.0.8) to identify differentially ASE between the two sample groups. Briefly, rMATS uses a modified version of the generalized linear mixed model to detect differentially ASE from RNA-Seq data with replicates, while controlling for changes in expression at gene-level. In addition, it also accounts for exonspecific sequencing coverage in individual samples as well as variation in exon splicing levels among replicates. rMATS was run using the default parameters and then significant splicing events were filtered using a stringent cut-off of FDR ≤ 0.05and deltaPSI ³ 10%.
The R package, Maser, was used for extracting and visualizing splice events. and then significant events were extracted and further analyzed using the R package.
Motif Enrichment Analysis.
We employed rMAPS2 analysis to determine the binding patterns of splicing factors and RNA binding proteins within significantly detected exon skipping ASE between two treatment groups. We collected well-characterized 115 known binding sites of RNA 
